Proteomic analysis for the early detection and rational treatment of cancer - Realistic hope?

Annals of Oncology

Volumn 16, Issue 1, 2005, Pages 16-22

  Posadas, E M ^a,b,c   Simpkins, F ^b   Liotta, L A ^a,b   MacDonald, C ^b   Kohn, E C ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NONE   (United States)

Author keywords

Cancer; Early detection; Laser capture microdissection; Proteomics; Surface enhanced laser desorption ionization; Tissue lysate arrays

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CETUXIMAB; GEFITINIB; HEAT SHOCK PROTEIN 27; IMATINIB; MAMMAGLOBIN; PANCREATITIS ASSOCIATED PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN 14 3 3; PROTEOLIPID PROTEIN; PROTEOME; SORAFENIB; TRASTUZUMAB;

BIOINFORMATICS; BREAST CANCER; CANCER THERAPY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE QUALITY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INDIVIDUALIZATION; LASER CAPTURE MICRODISSECTION; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR MECHANICS; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TECHNOLOGY; WESTERN BLOTTING;

BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; NEOPLASMS; PANCREATIC NEOPLASMS; PATIENT CARE PLANNING; PROSTATIC NEOPLASMS; PROTEOMICS;

EID: 12344289403     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi004     Document Type: Review

References (41)

1. Verma M, Wright GL Jr, Hanash SM et al. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann N Y Acad Sci 2001; 945: 103-115.
2. Michener CM, Ardekani AM, Petricoin EF 3rd et al. Genomics and proteomics: application of novel technology to early detection and prevention of cancer. Cancer Detect Prev 2002; 26: 249-255.
3. Gorg A, Obermaier C, Boguth G et al. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000; 21: 1037-1053.
4. Hanash SM. Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status. Electrophoresis 2000; 21: 1202-1209.
5. David R, Richter MP, Beck-Sickinger AG. Expressed protein ligation. Method and applications. Eur J Biochem 2004; 271: 663-677.
6. Emmert-Buck MR, Bonner RF, Smith PD et al. Laser capture microdissection. Science 1996; 274: 998-1001.
7. Jones MB, Krutzsch H, Shu H et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002; 2: 76-84.
8. Ornstein DK, Gillespie JW, Paweletz CP et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 2000; 21: 2235-2242.
9. Jones MB, Michener CM, Blanchette JO et al. The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res 2003; 9: 44-51.
10. Miller JC, Zhou H, Kwekel J et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003; 3: 56-63.
11. Knezevic V, Leethanakul C, Bichsel VE et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 2001; 1: 1271-1278.
12. Paweletz CP, Liotta LA, Petricoin EF 3rd. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology 2001; 57 (4 Suppl 1): 160-163.
13. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 2000; 1: 48-56.
14. MacBeath G. Protein microarrays and proteomics. Nat Genet 2002; 32 (Suppl): 526-532.
15. Zhu H, Snyder M. Protein chip technology. Curr Opin Chem Biol 2003; 7: 55-63.
16. Lal SP, Christopherson RI, dos Remedios CG. Antibody arrays: an embryonic but rapidly growing technology. Drug Discov Today 2002; 7 (18 Suppl): S143-S149.
17. Wilson DS, Nock S. Recent developments in protein microarray technology. Angew Chem Int Ed Engl 2003; 42: 494-500.
18. Posadas EM, Hussain M, Espina V et al. A phase II clinical trial with proteomic profiling of imatinib mesylate in patients with refractory or relapsed epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2004; 23: 14S (Abstr 965).
19. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000; 21: 1164-1177.
20. Petricoin EF 3rd, Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576-1578.
21. Petricoin EF, Zoon KC, Kohn EC et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002; 1: 683-695.
22. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-577.
23. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003; 21 (10 Suppl): 200-205.
24. Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353: 1207-1210.
25. Cohen LS, Escobar PF, Scharm C et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 2001; 82: 40-48.
26. Conrads TP, Fusaro VA, Ross S et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 2004; 11: 163-178.
27. Brawer MK. Prostate-specific antigen: current status. CA Cancer J Clin 1999; 49: 264-281.
28. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
29. Grubb RL, Calvert VS, Wulkuhle JD et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 2003; 3: 2142-2146.
30. Ornstein DK, Englert C, Gillespie JW et al. Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium. Clin Cancer Res 2000; 6: 353-356.
31. Wright GL Jr, Cazares LH, Leung SM et al. Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 1999; 2: 264-276.
32. Zheng Y, Xu Y, Ye B et al. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 2003; 98: 2576-2582.
33. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292: 587-592.
34. Lehrer S, Roboz J, Ding H et al. Putative protein markers in the sera of men with prostatic neoplasms. BJU Int 2003; 92: 223-225.
35. Li J, White N, Zhang Z et al. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J Urol 2004; 171: 1782-1787.
36. Koopmann J, Zhang Z, White N et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10: 860-868.
37. Rosty C, Christa L, Kuzdzal S et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002; 62: 1868-1875.
38. Petricoin EE, Paweletz CP, Liotta LA. Clinical applications of proteomics: proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia 2002; 7: 433-440.
39. Li J, Zhang Z, Rosenzweig J et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-1304.
40. Rui Z, Jian-Guo J, Yuan-Peng T et al. Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics 2003; 3: 433-439.
41. Carter D, Douglass JF, Cornellison CD et al. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry 2002; 41: 6714-6722.